Jessica Nance, MD, MS, discusses maximizing gene therapy efficiency by selecting vectors for gene size, tissue targeting, and low exposure, and focusing on precise promoters for expression. This is a ...
Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...
Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...
We use the AdenoX Rapid Titer kit (Clontech now Takara Bio) for this service. This immunohistochemical assay involves making 3 serials dilutions of the virus and infecting 6 wells of a 24-well plate ...
A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that envelop genetic material of adeno-associated viruses (AAV), to improve gene ...
OXB to demonstrate how its global, multi-vector CDMO platform is positioned to capture growth in the cell and gene therapy marketEvent to ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Viralgen, the gene therapy CDMO coined by Bayer’s Asklepios BioPharmaceutical, is wading into commercial waters. The Spanish contractor on Wednesday said it cut the ribbon on the first $83 million ...
Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results